Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology 2015, 151: 1110-1112. PMID: 26107994, DOI: 10.1001/jamadermatol.2015.1520.Peer-Reviewed Original ResearchConceptsJanus kinase inhibitorTreatment of vitiligoKinase inhibitorsPathogenesis-directed therapyPathogenesis of vitiligoOral JanusSignificant repigmentationTherapeutic optionsCommon conditionEffective treatmentVitiligoAdditional studiesTofacitinib citrateTreatmentInhibitorsPatientsPathogenesisRepigmentationTherapyTreatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. Journal Of The American Academy Of Dermatology 2015, 73: 395-399. PMID: 26194706, DOI: 10.1016/j.jaad.2015.06.045.Peer-Reviewed Original ResearchConceptsSevere atopic dermatitisAtopic dermatitisTofacitinib citrateBody surface area involvementEdema/papulationRecalcitrant atopic dermatitisAD indexSurface area involvementWeeks of treatmentPlacebo control groupAdverse eventsConsecutive patientsArea involvementStandard treatmentControl groupDermatitisSmall sample sizeTreatmentPatientsPossibility of biasSample sizeLichenificationCitrateErythemaScoring